These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 2300537)

  • 1. Effects of first-pass metabolism on metabolite mean residence time determination after oral administration of parent drug.
    Chan KK; Gibaldi M
    Pharm Res; 1990 Jan; 7(1):59-63. PubMed ID: 2300537
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mean residence time of oral drugs undergoing first-pass and linear reversible metabolism.
    Cheng H; Jusko WJ
    Pharm Res; 1993 Jan; 10(1):8-13. PubMed ID: 8430064
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A general model of metabolite kinetics following intravenous and oral administration of the parent drug.
    Weiss M
    Biopharm Drug Dispos; 1988; 9(2):159-76. PubMed ID: 3370305
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of metabolites in bioequivalency assessment. II. Drugs with linear pharmacokinetics and first-pass effect.
    Chen ML; Jackson AJ
    Pharm Res; 1995 May; 12(5):700-8. PubMed ID: 7479556
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A method for calculating the mean absorption time of drugs undergoing reversible and first-pass metabolism.
    Cheng H; Shum L
    Biopharm Drug Dispos; 1993 Jan; 14(1):71-9. PubMed ID: 8427946
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mean residence time of drugs administered non-instantaneously and undergoing linear tissue distribution and reversible metabolism and linear or non-linear elimination from the central compartment.
    Cheng H
    Biopharm Drug Dispos; 1995 May; 16(4):259-67. PubMed ID: 7548775
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mean time and first-pass metabolism.
    Brockmeier D; Ostrowski J
    Eur J Clin Pharmacol; 1985; 29(1):45-8. PubMed ID: 3840437
    [TBL] [Abstract][Full Text] [Related]  

  • 8. First-pass elimination. Basic concepts and clinical consequences.
    Pond SM; Tozer TN
    Clin Pharmacokinet; 1984; 9(1):1-25. PubMed ID: 6362950
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The ratio of first to zeroth moments of the plasma profile of an oral drug undergoing first-pass and linear reversible metabolism.
    Cheng H
    Biopharm Drug Dispos; 1995 Dec; 16(9):791-6. PubMed ID: 8580402
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Constant-rate intravenous infusion methods for estimating steady-state volumes of distribution and mean residence times in the body for drugs undergoing reversible metabolism.
    Cheng H; Jusko WJ
    Pharm Res; 1990 Jun; 7(6):628-32. PubMed ID: 2367330
    [TBL] [Abstract][Full Text] [Related]  

  • 11. On the accuracy of estimation of basic pharmacokinetic parameters by the traditional noncompartmental equations and the prediction of the steady-state volume of distribution in obese patients based upon data derived from normal subjects.
    Berezhkovskiy LM
    J Pharm Sci; 2011 Jun; 100(6):2482-97. PubMed ID: 21254063
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Primary, secondary, and tertiary metabolite kinetics.
    St-Pierre MV; Xu X; Pang KS
    J Pharmacokinet Biopharm; 1988 Oct; 16(5):493-527. PubMed ID: 3199316
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral bioavailability and first-pass effects.
    Kwan KC
    Drug Metab Dispos; 1997 Dec; 25(12):1329-36. PubMed ID: 9394021
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Types of mean residence times.
    Wagner JG
    Biopharm Drug Dispos; 1988; 9(1):41-57. PubMed ID: 3342284
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Computer simulations for bioequivalence trials: Selection of analyte in BCS class II and IV drugs with first-pass metabolism, two metabolic pathways and intestinal efflux transporter.
    Mangas-Sanjuan V; Navarro-Fontestad C; García-Arieta A; Trocóniz IF; Bermejo M
    Eur J Pharm Sci; 2018 May; 117():193-203. PubMed ID: 29452210
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Computer simulations of bioequivalence trials: selection of design and analyte in BCS drugs with first-pass hepatic metabolism: linear kinetics (I).
    Fernández-Teruel C; Nalda Molina R; González-Alvarez I; Navarro-Fontestad C; García-Arieta A; Casabó VG; Bermejo M
    Eur J Pharm Sci; 2009 Jan; 36(1):137-46. PubMed ID: 19028574
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Determination of volume of distribution at steady state with complete consideration of the kinetics of protein and tissue binding in linear pharmacokinetics.
    Berezhkovskiy LM
    J Pharm Sci; 2004 Feb; 93(2):364-74. PubMed ID: 14705193
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mean residence times and distribution volumes for drugs undergoing linear reversible metabolism and tissue distribution and linear or nonlinear elimination from the central compartments.
    Cheng HY; Jusko WJ
    Pharm Res; 1991 Apr; 8(4):508-11. PubMed ID: 1871048
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation between in silico physicochemical characteristics of drugs and their mean residence time in human and dog.
    Grabowski T; Jaroszewski JJ; Gad SC; Feder M
    Int J Toxicol; 2012; 31(1):25-33. PubMed ID: 22215410
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolite formation pharmacokinetics: rate and extent of metabolite formation determined by deconvolution.
    Karol MD; Goodrich S
    Pharm Res; 1988 Jun; 5(6):347-51. PubMed ID: 2469080
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.